Amgen Inc. Files Definitive Proxy Materials
Ticker: AMGN · Form: DEFA14A · Filed: Apr 29, 2025 · CIK: 318154
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, corporate-governance
Related Tickers: AMGN
TL;DR
Amgen filed its final proxy docs, get ready to vote.
AI Summary
Amgen Inc. filed a Definitive Additional Materials proxy statement on April 29, 2025. This filing is related to the company's proxy statement and is not a preliminary or confidential version. Amgen Inc. is a biotechnology company incorporated in Delaware.
Why It Matters
This filing indicates that Amgen is proceeding with its shareholder communication and voting process, which is a standard part of corporate governance for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine regulatory filing for a large, established company and does not contain new material information that would inherently increase risk.
Key Players & Entities
- AMGEN INC. (company) — Registrant
- 0000950170-25-060241 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- DE (state) — State of Incorporation
- 1934 Act (regulation) — SEC Act
FAQ
What type of filing is this DEFA14A for Amgen Inc.?
This filing is classified as Definitive Additional Materials, filed on April 29, 2025, under Accession Number 0000950170-25-060241.
What is Amgen Inc.'s primary business as indicated in the filing?
Amgen Inc. is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.
Where is Amgen Inc. incorporated?
Amgen Inc. is incorporated in Delaware (DE).
What is the fiscal year end for Amgen Inc.?
Amgen Inc.'s fiscal year ends on December 31 (1231).
What is the filing fee status for this DEFA14A?
The filing indicates that no fee was required for this filing.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 29, 2025 regarding AMGEN INC (AMGN).